Latest Animal Health News

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Apiam Animal Health Limited shareholders are set to vote on a scheme of arrangement offering $0.87 cash per share or a mix of cash and unlisted scrip in a new holding company controlled by Adamantem Capital. The Independent Expert deems the cash offer fair and reasonable, while scrip options carry liquidity and minority risks.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Terragen Holdings has secured a major purchase order from Mort & Co Fertilisers for its Great Land Plus® bio-stimulant, projecting a significant sales boost in 2026. This deal underscores growing demand for sustainable agricultural solutions.

Elders Limited reported a robust FY25 with a 12% rise in underlying EBIT to $143.5 million and declared a fully franked final dividend of 18 cents per share. The agribusiness is optimistic about FY26, buoyed by strategic acquisitions and a new divisional model.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.